Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
2008-05-06
2008-05-06
Fetterolf, Brandon (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
C424S184100
Reexamination Certificate
active
10161651
ABSTRACT:
The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, without prior modification of the cell binding agent. These conjugates are useful as therapeutic agents which are delivered specifically to target cells and are cytotoxic.
REFERENCES:
patent: 4361650 (1982-11-01), Asai et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5416064 (1995-05-01), Blättler et al.
patent: 5612474 (1997-03-01), Patel
patent: 6316003 (2001-11-01), Frankel et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 6716821 (2004-04-01), Zhao et al.
patent: 2006408 (1990-06-01), None
patent: 0 425 235 (1991-05-01), None
patent: 1 258 255 (2002-11-01), None
patent: WO 01/24763 (2001-04-01), None
patent: WO 02/16368 (2002-02-01), None
patent: WO 02/094325 (2002-11-01), None
patent: WO 03/057163 (2003-07-01), None
Pietersz, Geoffrey (Bioconjugate Chemistry 1990; 1: 89-94).
Lewis et al. (Bioconjugate Chem. 2001; 12: 320-324).
S. Morris Kupchan, et al., “Structural Requirements for Antileukemic Activity among the Naturally Occurring and Semisynthetic Maytansinoids,” 1978, pp. 31-37, Journal of Medicinal Chemistry, vol. 21, No. 1.
Akiyoshi Kawai, et al., “Chemical Modification of Ansamitocins. III. Synthesis and Biological Effects of 3-Acyl Esters of Maytansinol,” 1984, pp. 3441-3451, Chemical and Pharmaceutical Bulletin, vol. 32, No. 9.
C Liu, et al. “Cure of human small cell lung cancer xenografts in SCID mice by a hN901-maytansinoid immunoconjugate”Proceedings of the American Association for Cancer Research Annual Meeting, vol. 38, No. 0, 1997, p. 29.
Cynthia Ladino, et al. “Folate-maytansinoid: target-selective drugs of low-molecular weight”International Journal of Cancer, 73(6), pp. 859-864.
Smith, S, “Technology evaluation: C242-DM1, ImmunoGen Inc,” Current Opinion in Molecular Therapeutics; vol. 3 (2), pp. 198-203, 2001; XP-008011026.
Liu, C. et. al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids,” Proc. Natl. Acad. Aci. USA, vol. 93, pp. 8618-8623, Aug. 1996; XP-002181060.
Chari, R. et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs,” 6175 Cancer Research, 52(Jan. 1, 2002), No. 1, Baltimore, MD, USA; XP 000453560.
Chari Ravi V. J.
Widdison Wayne C.
Fetterolf Brandon
Immunogen Inc.
LandOfFree
Methods for preparation of cytotoxic conjugates of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preparation of cytotoxic conjugates of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preparation of cytotoxic conjugates of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926005